{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:06:48Z","timestamp":1787890008217,"version":"build-2784847793"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2012,6,7]],"date-time":"2012-06-07T00:00:00Z","timestamp":1339027200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Cancer"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1038\/nrc3297","type":"journal-article","created":{"date-parts":[[2012,6,7]],"date-time":"2012-06-07T05:02:45Z","timestamp":1339045365000},"page":"494-501","source":"Crossref","is-referenced-by-count":132,"title":["Managing drug resistance in cancer: lessons from HIV therapy"],"prefix":"10.1038","volume":"12","author":[{"given":"Christoph","family":"Bock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lengauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,6,7]]},"reference":[{"key":"BFnrc3297_CR1","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMra025195","volume":"350","author":"F Clavel","year":"2004","unstructured":"Clavel, F. & Hance, A. J. HIV drug resistance. N. Engl. J. Med. 350, 1023\u20131035 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrc3297_CR2","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","volume":"53","author":"MM Gottesman","year":"2002","unstructured":"Gottesman, M. M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615\u2013627 (2002).","journal-title":"Annu. Rev. Med."},{"key":"BFnrc3297_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2009.10.002","volume":"85","author":"S Broder","year":"2010","unstructured":"Broder, S. The development of antiretroviral therapy and its impact on the HIV-1\/AIDS pandemic. Antiviral Res. 85, 1\u201318 (2010).","journal-title":"Antiviral Res."},{"key":"BFnrc3297_CR4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nrd892","volume":"1","author":"AL Hopkins","year":"2002","unstructured":"Hopkins, A. L. & Groom, C. R. The druggable genome. Nature Rev. Drug Discov. 1, 727\u2013730 (2002).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrc3297_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1377\/hlthaff.24.1.67","volume":"24","author":"TR Fleming","year":"2005","unstructured":"Fleming, T. R. Surrogate endpoints and FDA's accelerated approval process. Health Aff. (Millwood) 24, 67\u201378 (2005).","journal-title":"Health Aff. (Millwood)"},{"key":"BFnrc3297_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/jmv.21971","volume":"83","author":"S Reuter","year":"2011","unstructured":"Reuter, S. et al. Changes in the HIV-1 mutational profile before first-line HAART in the RESINA cohort. J. Med. Virol. 83, 187\u2013195 (2011).","journal-title":"J. Med. Virol."},{"key":"BFnrc3297_CR7","doi-asserted-by":"crossref","unstructured":"The SPREAD programme. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 22, 625\u2013635 (2008).","DOI":"10.1097\/QAD.0b013e3282f5e062"},{"key":"BFnrc3297_CR8","doi-asserted-by":"crossref","unstructured":"Young, T. N., Arens, F. J., Kennedy, G. E., Laurie, J. W. & Rutherford, G. Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure. Cochrane Database Syst Rev. CD002835 (2007).","DOI":"10.1002\/14651858.CD002835.pub3"},{"key":"BFnrc3297_CR9","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2012.02.021","volume":"148","author":"DE Goldberg","year":"2012","unstructured":"Goldberg, D. E., Siliciano, R. F. & Jacobs, W. R. Jr. Outwitting evolution: fighting drug-resistant TB, malaria, and HIV. Cell 148, 1271\u20131283 (2012).","journal-title":"Cell"},{"key":"BFnrc3297_CR10","volume-title":"Antiretroviral Resistance in Clinical Practice","author":"K Metzner","year":"2006","unstructured":"Metzner, K. in Antiretroviral Resistance in Clinical Practice Ch. 11 (ed. Geretti, A. M.) (Mediscript, 2006)."},{"key":"BFnrc3297_CR11","doi-asserted-by":"publisher","first-page":"7681","DOI":"10.1073\/pnas.97.14.7681","volume":"97","author":"RM Ribeiro","year":"2000","unstructured":"Ribeiro, R. M. & Bonhoeffer, S. Production of resistant HIV mutants during antiretroviral therapy. Proc. Natl Acad. Sci. USA 97, 7681\u20137686 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3297_CR12","unstructured":"U.S. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. AIDS info \n                    [online]\n                    \n                  , (2012)."},{"key":"BFnrc3297_CR13","first-page":"180","volume":"13","author":"A Imaz","year":"2011","unstructured":"Imaz, A., Falco, V. & Ribera, E. Antiretroviral salvage therapy for multiclass drug-resistant HIV-1-infected patients: from clinical trials to daily clinical practice. AIDS Rev. 13, 180\u2013193 (2011).","journal-title":"AIDS Rev."},{"key":"BFnrc3297_CR14","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1111\/j.1469-0691.2010.03353.x","volume":"16","author":"F Ceccherini-Silberstein","year":"2010","unstructured":"Ceccherini-Silberstein, F., Cento, V., Calvez, V. & Perno, C. F. The use of human immunodeficiency virus resistance tests in clinical practice. Clin. Microbiol. Infect. 16, 1511\u20131517 (2010).","journal-title":"Clin. Microbiol. Infect."},{"key":"BFnrc3297_CR15","first-page":"156","volume":"18","author":"VA Johnson","year":"2010","unstructured":"Johnson, V. A. et al. Update of the drug resistance mutations in HIV-1: December 2010. Top. HIV Med. 18, 156\u2013163 (2010).","journal-title":"Top. HIV Med."},{"key":"BFnrc3297_CR16","doi-asserted-by":"publisher","first-page":"e11505","DOI":"10.1371\/journal.pone.0011505","volume":"5","author":"D Frentz","year":"2010","unstructured":"Frentz, D. et al. Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. PLoS ONE 5, e11505 (2010).","journal-title":"PLoS ONE"},{"key":"BFnrc3297_CR17","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrmicro1477","volume":"4","author":"T Lengauer","year":"2006","unstructured":"Lengauer, T. & Sing, T. Bioinformatics-assisted anti-HIV therapy. Nature Rev. Microbiol. 4, 790\u2013797 (2006).","journal-title":"Nature Rev. Microbiol."},{"key":"BFnrc3297_CR18","first-page":"77","volume":"13","author":"AM Vandamme","year":"2011","unstructured":"Vandamme, A. M. et al. European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev. 13, 77\u2013108 (2011).","journal-title":"AIDS Rev."},{"key":"BFnrc3297_CR19","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S1473-3099(10)70319-4","volume":"11","author":"LP Vandekerckhove","year":"2011","unstructured":"Vandekerckhove, L. P. et al. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect. Dis. 11, 394\u2013407 (2011).","journal-title":"Lancet Infect. Dis."},{"key":"BFnrc3297_CR20","doi-asserted-by":"publisher","first-page":"i399","DOI":"10.1093\/bioinformatics\/btn141","volume":"24","author":"M Rosen-Zvi","year":"2008","unstructured":"Rosen-Zvi, M. et al. Selecting anti-HIV therapies based on a variety of genomic and clinical factors. Bioinformatics 24, i399\u2013406 (2008).","journal-title":"Bioinformatics"},{"key":"BFnrc3297_CR21","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1086\/597305","volume":"199","author":"A Altmann","year":"2009","unstructured":"Altmann, A. et al. Predicting the response to combination antiretroviral therapy: retrospective validation of geno2pheno-THEO on a large clinical database. J. Infect. Dis. 199, 999\u20131006 (2009).","journal-title":"J. Infect. Dis."},{"key":"BFnrc3297_CR22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000332000","volume":"55","author":"T Lengauer","year":"2012","unstructured":"Lengauer, T. Bioinformatical assistance of selecting anti-HIV therapies: where do we stand? Intervirology 55, 108\u2013112 (2012).","journal-title":"Intervirology"},{"key":"BFnrc3297_CR23","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.cell.2012.02.015","volume":"148","author":"MS Glickman","year":"2012","unstructured":"Glickman, M. S. & Sawyers, C. L. Converting cancer therapies into cures: lessons from infectious diseases. Cell 148, 1089\u20131098 (2012).","journal-title":"Cell"},{"key":"BFnrc3297_CR24","doi-asserted-by":"publisher","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","volume":"68","author":"VT DeVita Jr","year":"2008","unstructured":"DeVita, V. T. Jr & Chu, E. A history of cancer chemotherapy. Cancer Res. 68, 8643\u20138653 (2008).","journal-title":"Cancer Res."},{"key":"BFnrc3297_CR25","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1007\/s00018-008-8111-5","volume":"65","author":"H Lage","year":"2008","unstructured":"Lage, H. An overview of cancer multidrug resistance: a still unsolved problem. Cell. Mol. Life Sci. 65, 3145\u20133167 (2008).","journal-title":"Cell. Mol. Life Sci."},{"key":"BFnrc3297_CR26","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nrd2089","volume":"5","author":"JE Dancey","year":"2006","unstructured":"Dancey, J. E. & Chen, H. X. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nature Rev. Drug Discov. 5, 649\u2013659 (2006).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrc3297_CR27","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd3216","volume":"9","author":"S Kummar","year":"2010","unstructured":"Kummar, S. et al. Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nature Rev. Drug Discov. 9, 843\u2013856 (2010).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrc3297_CR28","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nm.2323","volume":"17","author":"L Chin","year":"2011","unstructured":"Chin, L., Andersen, J. N. & Futreal, P. A. Cancer genomics: from discovery science to personalized medicine. Nature Med. 17, 297\u2013303 (2011).","journal-title":"Nature Med."},{"key":"BFnrc3297_CR29","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nrd3181","volume":"9","author":"RL Schilsky","year":"2010","unstructured":"Schilsky, R. L. Personalized medicine in oncology: the future is now. Nature Rev. Drug Discov. 9, 363\u2013366 (2010).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrc3297_CR30","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1093\/jnci\/djr246","volume":"103","author":"RW Humphrey","year":"2011","unstructured":"Humphrey, R. W. et al. Opportunities and challenges in the development of experimental drug combinations for cancer. J. Natl Cancer Inst. 103, 1222\u20131226 (2011).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrc3297_CR31","doi-asserted-by":"publisher","first-page":"5232","DOI":"10.1158\/1078-0432.CCR-07-1385","volume":"13","author":"EL Kwak","year":"2007","unstructured":"Kwak, E. L., Clark, J. W. & Chabner, B. Targeted agents: the rules of combination. Clin. Cancer Res. 13, 5232\u20135237 (2007).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc3297_CR32","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nature06914","volume":"452","author":"L Chin","year":"2008","unstructured":"Chin, L. & Gray, J. W. Translating insights from the cancer genome into clinical practice. Nature 452, 553\u2013563 (2008).","journal-title":"Nature"},{"key":"BFnrc3297_CR33","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/nature03095","volume":"432","author":"C Sawyers","year":"2004","unstructured":"Sawyers, C. Targeted cancer therapy. Nature 432, 294\u2013297 (2004).","journal-title":"Nature"},{"key":"BFnrc3297_CR34","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cell.2011.09.016","volume":"147","author":"WR Sellers","year":"2011","unstructured":"Sellers, W. R. A blueprint for advancing genetics-based cancer therapy. Cell 147, 26\u201331 (2011).","journal-title":"Cell"},{"key":"BFnrc3297_CR35","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJM199811263392207","volume":"339","author":"CK Osborne","year":"1998","unstructured":"Osborne, C. K. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med. 339, 1609\u20131618 (1998).","journal-title":"N. Engl. J. Med."},{"key":"BFnrc3297_CR36","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nrclinonc.2009.216","volume":"7","author":"FJ Esteva","year":"2010","unstructured":"Esteva, F. J., Yu, D., Hung, M. C. & Hortobagyi, G. N. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nature Rev. Clin. Oncol. 7, 98\u2013107 (2010).","journal-title":"Nature Rev. Clin. Oncol."},{"key":"BFnrc3297_CR37","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1158\/1078-0432.CCR-10-2922","volume":"17","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian, H. M., Baccarani, M., Jabbour, E., Saglio, G. & Cortes, J. E. Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy. Clin. Cancer Res. 17, 1674\u20131683 (2011).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc3297_CR38","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S1470-2045(03)01137-9","volume":"4","author":"SS Sridhar","year":"2003","unstructured":"Sridhar, S. S., Seymour, L. & Shepherd, F. A. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol. 4, 397\u2013406 (2003).","journal-title":"Lancet Oncol."},{"key":"BFnrc3297_CR39","doi-asserted-by":"publisher","first-page":"4384s","DOI":"10.1158\/1078-0432.CCR-06-0098","volume":"12","author":"RK Thomas","year":"2006","unstructured":"Thomas, R. K., Weir, B. & Meyerson, M. Genomic approaches to lung cancer. Clin Cancer Res 12, 4384s\u20134391s (2006).","journal-title":"Clin Cancer Res"},{"key":"BFnrc3297_CR40","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nrc3218","volume":"12","author":"KT Flaherty","year":"2012","unstructured":"Flaherty, K. T., Hodi, F. S. & Fisher, D. E. From genes to drugs: targeted strategies for melanoma. Nature Rev. Cancer 12, 349\u2013361 (2012).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc3297_CR41","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1158\/1078-0432.CCR-09-1947","volume":"17","author":"V Abramson","year":"2011","unstructured":"Abramson, V. & Arteaga, C. L. New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available. Clin. Cancer Res. 17, 952\u2013958 (2011).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc3297_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/leu.2010.238","volume":"25","author":"D Bixby","year":"2011","unstructured":"Bixby, D. & Talpaz, M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 25, 7\u201322 (2011).","journal-title":"Leukemia"},{"key":"BFnrc3297_CR43","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/CCO.0b013e32834fca92","volume":"24","author":"R Dummer","year":"2012","unstructured":"Dummer, R. & Flaherty, K. T. Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. Curr. Opin. Oncol. 24, 150\u2013154 (2012).","journal-title":"Curr. Opin. Oncol."},{"key":"BFnrc3297_CR44","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nrc2683","volume":"9","author":"JM Hoskins","year":"2009","unstructured":"Hoskins, J. M., Carey, L. A. & McLeod, H. L. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nature Rev. Cancer 9, 576\u2013586 (2009).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc3297_CR45","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrclinonc.2010.97","volume":"7","author":"DL Wheeler","year":"2010","unstructured":"Wheeler, D. L., Dunn, E. F. & Harari, P. M. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nature Rev. Clin. Oncol. 7, 493\u2013507 (2010).","journal-title":"Nature Rev. Clin. Oncol."},{"key":"BFnrc3297_CR46","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrd2033","volume":"5","author":"KA Phillips","year":"2006","unstructured":"Phillips, K. A., Van Bebber, S. & Issa, A. M. Diagnostics and biomarker development: priming the pipeline. Nature Rev. Drug Discov. 5, 463\u2013469 (2006).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrc3297_CR47","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc1590","volume":"5","author":"M Dean","year":"2005","unstructured":"Dean, M., Fojo, T. & Bates, S. Tumour stem cells and drug resistance. Nature Rev. Cancer 5, 275\u2013284 (2005).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc3297_CR48","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1196\/annals.1339.024","volume":"1059","author":"S Decker","year":"2005","unstructured":"Decker, S. & Sausville, E. A. Preclinical modeling of combination treatments: fantasy or requirement? Ann. N. Y. Acad. Sci. 1059, 61\u201369 (2005).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"BFnrc3297_CR49","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1200\/JCO.2004.04.077","volume":"22","author":"DJ Samson","year":"2004","unstructured":"Samson, D. J., Seidenfeld, J., Ziegler, K. & Aronson, N. Chemotherapy sensitivity and resistance assays: a systematic review. J. Clin. Oncol. 22, 3618\u20133630 (2004).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc3297_CR50","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1158\/1078-0432.CCR-09-2878","volume":"16","author":"X Dong","year":"2010","unstructured":"Dong, X. et al. Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clin. Cancer Res. 16, 1442\u20131451 (2010).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc3297_CR51","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1158\/1535-7163.MCT-11-0233","volume":"10","author":"M Hidalgo","year":"2011","unstructured":"Hidalgo, M. et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol. Cancer Ther. 10, 1311\u20131316 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"BFnrc3297_CR52","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/nrg2795","volume":"11","author":"RD Hawkins","year":"2010","unstructured":"Hawkins, R. D., Hon, G. C. & Ren, B. Next-generation genomics: an integrative approach. Nature Rev. Genet. 11, 476\u2013486 (2010).","journal-title":"Nature Rev. Genet."},{"key":"BFnrc3297_CR53","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nmeth0411-311","volume":"8","author":"T Kalisky","year":"2011","unstructured":"Kalisky, T. & Quake, S. R. Single-cell genomics. Nature Methods 8, 311\u2013314 (2011).","journal-title":"Nature Methods"},{"key":"BFnrc3297_CR54","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrg2626","volume":"11","author":"ML Metzker","year":"2010","unstructured":"Metzker, M. L. Sequencing technologies - the next generation. Nature Rev. Genet. 11, 31\u201346 (2010).","journal-title":"Nature Rev. Genet."},{"key":"BFnrc3297_CR55","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nmeth.1439","volume":"7","author":"SS Shen-Orr","year":"2010","unstructured":"Shen-Orr, S. S. et al. Cell type-specific gene expression differences in complex tissues. Nature Methods 7, 287\u2013289 (2010).","journal-title":"Nature Methods"},{"key":"BFnrc3297_CR56","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/msb.2011.47","volume":"7","author":"AL Cohen","year":"2011","unstructured":"Cohen, A. L. et al. A pharmacogenomic method for individualized prediction of drug sensitivity. Mol. Syst. Biol. 7, 513 (2011).","journal-title":"Mol. Syst. Biol."},{"key":"BFnrc3297_CR57","doi-asserted-by":"publisher","first-page":"96ra76","DOI":"10.1126\/scitranslmed.3002648","volume":"3","author":"JT Dudley","year":"2011","unstructured":"Dudley, J. T. et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med 3, 96ra76 (2011).","journal-title":"Sci Transl Med"},{"key":"BFnrc3297_CR58","doi-asserted-by":"publisher","first-page":"96ra77","DOI":"10.1126\/scitranslmed.3001318","volume":"3","author":"M Sirota","year":"2011","unstructured":"Sirota, M. et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 3, 96ra77 (2011).","journal-title":"Sci Transl Med"},{"key":"BFnrc3297_CR59","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1101\/gr.119867.110","volume":"22","author":"AF Fernandez","year":"2012","unstructured":"Fernandez, A. F. et al. A DNA methylation fingerprint of 1,628 human samples. Genome Res. 22, 407\u2013419 (2012).","journal-title":"Genome Res."},{"key":"BFnrc3297_CR60","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.cell.2010.12.032","volume":"144","author":"C Bock","year":"2011","unstructured":"Bock, C. et al. Reference Maps of Human ES and iPS Cell Variation Enable High-Throughput Characterization of Pluripotent Cell Lines. Cell 144, 439\u2013452 (2011).","journal-title":"Cell"},{"key":"BFnrc3297_CR61","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/459508a","volume":"459","author":"RA Gatenby","year":"2009","unstructured":"Gatenby, R. A. A change of strategy in the war on cancer. Nature 459, 508\u2013509 (2009).","journal-title":"Nature"},{"key":"BFnrc3297_CR62","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"BFnrc3297_CR63","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/nrd2876","volume":"8","author":"Y Feng","year":"2009","unstructured":"Feng, Y., Mitchison, T. J., Bender, A., Young, D. W. & Tallarico, J. A. Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds. Nature Rev. Drug Discov. 8, 567\u2013578 (2009).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrc3297_CR64","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/nrd2826","volume":"8","author":"EE Schadt","year":"2009","unstructured":"Schadt, E. E., Friend, S. H. & Shaywitz, D. A. A network view of disease and compound screening. Nature Rev. Drug Discov. 8, 286\u2013295 (2009).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrc3297_CR65","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/GIM.0b013e318220aaba","volume":"13","author":"JS Berg","year":"2011","unstructured":"Berg, J. S., Khoury, M. J. & Evans, J. P. Deploying whole genome sequencing in clinical practice and public health: Meeting the challenge one bin at a time. Genet. Med. 13, 499\u2013504 (2011).","journal-title":"Genet. Med."},{"key":"BFnrc3297_CR66","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature06913","volume":"452","author":"CL Sawyers","year":"2008","unstructured":"Sawyers, C. L. The cancer biomarker problem. Nature 452, 548\u2013552 (2008).","journal-title":"Nature"},{"key":"BFnrc3297_CR67","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrc3036","volume":"11","author":"RA Gatenby","year":"2011","unstructured":"Gatenby, R. A., Gillies, R. J. & Brown, J. S. Of cancer and cave fish. Nature Rev. Cancer 11, 237\u2013238 (2011).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc3297_CR68","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1176\/appi.ajp.160.4.636","volume":"160","author":"II Gottesman","year":"2003","unstructured":"Gottesman, I. I. & Gould, T. D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 160, 636\u2013645 (2003).","journal-title":"Am. J. Psychiatry"},{"key":"BFnrc3297_CR69","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/nrg2381","volume":"9","author":"M Burmeister","year":"2008","unstructured":"Burmeister, M., McInnis, M. G. & Zollner, S. Psychiatric genetics: progress amid controversy. Nature Rev. Genet. 9, 527\u2013540 (2008).","journal-title":"Nature Rev. Genet."},{"key":"BFnrc3297_CR70","doi-asserted-by":"publisher","first-page":"8271","DOI":"10.1073\/pnas.112177799","volume":"99","author":"N Beerenwinkel","year":"2002","unstructured":"Beerenwinkel, N. et al. Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype. Proc. Natl Acad. Sci. USA 99, 8271\u20138276 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3297_CR71","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2004.06.026","volume":"6","author":"G Szakacs","year":"2004","unstructured":"Szakacs, G. et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6, 129\u2013137 (2004).","journal-title":"Cancer Cell"},{"key":"BFnrc3297_CR72","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bbmt.2008.06.014","volume":"14","author":"RA Bray","year":"2008","unstructured":"Bray, R. A. et al. National marrow donor program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants. Biol. Blood Marrow Transplant 14, 45\u201353 (2008).","journal-title":"Biol. Blood Marrow Transplant"},{"key":"BFnrc3297_CR73","doi-asserted-by":"publisher","first-page":"e1000257","DOI":"10.1371\/journal.pcbi.1000257","volume":"5","author":"EM Airoldi","year":"2009","unstructured":"Airoldi, E. M. et al. Predicting cellular growth from gene expression signatures. PLoS Comput. Biol. 5, e1000257 (2009).","journal-title":"PLoS Comput. Biol."},{"key":"BFnrc3297_CR74","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","volume":"363","author":"KT Flaherty","year":"2010","unstructured":"Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809\u2013819 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrc3297_CR75","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507\u20132516 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrc3297_CR76","doi-asserted-by":"publisher","first-page":"336","DOI":"10.18632\/oncotarget.262","volume":"2","author":"RB Corcoran","year":"2011","unstructured":"Corcoran, R. B., Settleman, J. & Engelman, J. A. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget 2, 336\u2013346 (2011).","journal-title":"Oncotarget"},{"key":"BFnrc3297_CR77","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1093\/bioinformatics\/bti654","volume":"21","author":"N Beerenwinkel","year":"2005","unstructured":"Beerenwinkel, N. et al. Computational methods for the design of effective therapies against drug resistant HIV strains. Bioinformatics 21, 3943\u20133950 (2005).","journal-title":"Bioinformatics"},{"key":"BFnrc3297_CR78","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607 (2012).","journal-title":"Nature"},{"key":"BFnrc3297_CR79","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nature11005","volume":"483","author":"MJ Garnett","year":"2012","unstructured":"Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570\u2013575 (2012).","journal-title":"Nature"}],"container-title":["Nature Reviews Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrc3297.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrc3297","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrc3297.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:34:18Z","timestamp":1684467258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrc3297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,7]]},"references-count":79,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["BFnrc3297"],"URL":"https:\/\/doi.org\/10.1038\/nrc3297","relation":{},"ISSN":["1474-175X","1474-1768"],"issn-type":[{"value":"1474-175X","type":"print"},{"value":"1474-1768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,7]]}}}